Marin Vulić

Seres Therapeutics (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

16h-index3.7kcitations29works0.32yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Bacterial Genetics and Biotechnology(12), DNA Repair Mechanisms(6), Clostridium difficile and Clostridium perfringens research(6), Antibiotic Resistance in Bacteria(5), Gut microbiota and health(4)

Publications29 total

The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiome
Nature Medicine·2026· 1 citedOpen Access
Sa1767: CANDIDATE BIOMARKERS OF MICROBIOME DISRUPTION FOR PATIENT SELECTION OR STRATIFICATION IN CLINICAL TRIALS OF MICROBIOME THERAPEUTICS IN ULCERATIVE COLITIS (UC)
Gastroenterology·2025
Sa1770: CHARACTERIZATION OF IBD MICROBIOMES IN MODELS OF MICROBIOME DISRUPTION AND INFLAMMATION TO EVALUATE CANDIDATE BIOMARKERS FOR PATIENT SELECTION
Gastroenterology·2025
2067. Preclinical Characterization of Rationally Designed Microbial Consortia to Prevent Bacterial Infections in Patients with Chronic Liver Disease
Open Forum Infectious Diseases·2023Open Access
2156. The Rational Design of SER-147: a Cultivated Microbial Consortium to Restore Colonization Resistance and Mitigate Infection in Chronic Liver Disease
Open Forum Infectious Diseases·2023Open Access
110: IMPACT OF SER-109, AN INVESTIGATIONAL MICROBIOME THERAPEUTIC, ON STOOL FATTY ACID METABOLITES IN A PHASE 3 RANDOMIZED TRIAL (ECOSPOR III) FOR TREATMENT OF RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION (CDI)
Gastroenterology·2022· 1 cited
130. Design and Preclinical Characterization of SER-155, an Investigational Cultivated Microbiome Therapeutic to Restore Colonization Resistance and Prevent Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation
Open Forum Infectious Diseases·2021· 2 citedOpen Access
681 SER-301, AN INVESTIGATIONAL, RATIONALLY-DESIGNED BACTERIAL CONSORTIUM FOR MILD-TO-MODERATE ULCERATIVE COLITIS, RECAPITULATES THE EFFECTS OF SER-287, A CONSORTIUM OF FIRMICUTE SPORES, ON REMISSION ASSOCIATED MICROBIAL METABOLITES AND HOST GENE EXPRESSION
Gastroenterology·2021· 1 cited
Reply to Lagier et al
The Journal of Infectious Diseases·2016Open Access
A Novel Microbiome Therapeutic Increases Gut Microbial Diversity and Prevents Recurrent<i>Clostridium difficile</i>Infection
The Journal of Infectious Diseases·2016· 310 citedOpen Access
HipBA–promoter structures reveal the basis of heritable multidrug tolerance
Nature·2015· 243 citedOpen Access
Vancomycin-Resistant Enterococcal iters Diminish Among Patients With Recurrent Clostridium difficile Infection After Administration of SER-109, A Novel Microbiome Agent
Open Forum Infectious Diseases·2015· 8 citedOpen Access
Tolerance of<i>Escherichia coli</i>to Fluoroquinolone Antibiotics Depends on Specific Components of the SOS Response Pathway
Genetics·2013· 99 citedOpen Access
Role of Oxidative Stress in Persister Tolerance
Antimicrobial Agents and Chemotherapy·2012· 266 citedOpen Access
Regulation of the Escherichia coli HipBA Toxin-Antitoxin System by Proteolysis
PLoS ONE·2012· 102 citedOpen Access
Population Dynamics of Escherichia coli in Surface Water1
JAWRA Journal of the American Water Resources Association·2011· 22 citedOpen Access
Ciprofloxacin Causes Persister Formation by Inducing the TisB toxin in Escherichia coli
PLoS Biology·2010· 764 citedOpen Access
SOS Response Induces Persistence to Fluoroquinolones in Escherichia coli
PLoS Genetics·2009· 519 citedOpen Access
Role of Global Regulators and Nucleotide Metabolism in Antibiotic Tolerance in <i>Escherichia coli</i>
Antimicrobial Agents and Chemotherapy·2008· 300 citedOpen Access
Direct Visualization of Horizontal Gene Transfer
Science·2008· 220 cited
page 1 of 2Next →

Frequent Co-authors

Matthew R. Henn(10), Kim Lewis(8), Christopher B. Ford(6), Elizabeth M. Halvorsen(5), Nicholas Beauchemin(5), Miroslav Radman(4), Edward J. O’Brien(4), Meghan Chafee(4), Asunción Martínez Martínez(4), Sahil Khanna(3), David N. Cook(3), Elizabeth Hohmann(3), Sonja Hansen(3), Mary‐Jane Lombardo(3), Jennifer R. Wortman(3), Melissa Mayol(3), Tobias Dörr(2), Darrell S. Pardi(2), Mary-Jane Lombardo(2), Jonathan Winkler(2)